Healthequity (HQY) Cash & Equivalents (2013 - 2026)

Healthequity's Cash & Equivalents history runs 14 years deep, the most recent figure standing at $265.4 million for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 7.82% year-over-year to $265.4 million; the TTM figure through Apr 2026 stood at $265.4 million (down 7.82% YoY), while the FY2026 annual figure was $318.9 million, up 7.76% from the prior year.
• Cash & Equivalents was $265.4 million for Q2 2026 at Healthequity, down from $318.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $404.0 million in Q1 2024 to a low of $161.2 million in Q2 2022.
• Historically, Cash & Equivalents has averaged $275.8 million across 5 years, with a median of $289.1 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents sank 78.11% in 2022, then surged 64.14% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $210.2 million in 2022, then jumped by 58.93% to $334.1 million in 2023, then retreated by 3.56% to $322.2 million in 2024, then declined by 4.01% to $309.3 million in 2025, then declined by 14.19% to $265.4 million in 2026.
• The last three Cash & Equivalents figures came in at $265.4 million (Q2 2026), $318.9 million (Q1 2026), and $309.3 million (Q4 2025), per Business Quant data.